Siemens Healthineers (OTCMKTS:SMMNY) Shares Up 1.7% – Should You Buy?

Shares of Siemens Healthineers AG (OTCMKTS:SMMNY) rose 1.7% during mid-day trading on Thursday . The stock traded as high as $24.98 and last traded at $24.98. Approximately 67,721 shares traded hands during trading, a decline of 31% from the average daily volume of 98,674 shares. The stock had previously closed at $24.56.

Analyst Ratings Changes

Several analysts have recently weighed in on SMMNY shares. Deutsche Bank Aktiengesellschaft downgraded Siemens Healthineers from a “buy” rating to a “hold” rating in a report on Thursday, December 4th. Zacks Research raised Siemens Healthineers from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Sanford C. Bernstein raised shares of Siemens Healthineers to a “strong-buy” rating in a report on Tuesday, January 13th. Citigroup reiterated a “buy” rating on shares of Siemens Healthineers in a research report on Friday, January 23rd. Finally, Royal Bank Of Canada started coverage on shares of Siemens Healthineers in a research report on Wednesday, December 17th. They set a “moderate buy” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Siemens Healthineers Stock Up 1.7%

The company’s fifty day moving average price is $25.62 and its two-hundred day moving average price is $26.38.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.